[go: up one dir, main page]

NZ795347B2 - Method of treating epilepsy - Google Patents

Method of treating epilepsy

Info

Publication number
NZ795347B2
NZ795347B2 NZ795347A NZ79534717A NZ795347B2 NZ 795347 B2 NZ795347 B2 NZ 795347B2 NZ 795347 A NZ795347 A NZ 795347A NZ 79534717 A NZ79534717 A NZ 79534717A NZ 795347 B2 NZ795347 B2 NZ 795347B2
Authority
NZ
New Zealand
Prior art keywords
use according
subject
medicament
seizure
focal
Prior art date
Application number
NZ795347A
Other versions
NZ795347A (en
Inventor
James Cassella
Lily Gong
Edwin S Kamemoto
Original Assignee
Alexza Pharmaceuticals Inc
Filing date
Publication date
Application filed by Alexza Pharmaceuticals Inc filed Critical Alexza Pharmaceuticals Inc
Publication of NZ795347A publication Critical patent/NZ795347A/en
Publication of NZ795347B2 publication Critical patent/NZ795347B2/en

Links

Abstract

Alprazolam formulated as an inhaled condensation aerosol and method for treating epilepsy and/or seizures.

Claims (8)

1. Use of alprazolam in the manufacture of a medicament for the acute treatment of an ongoing seizure in a subject, wherein the subject is selected from patients with partial (focal) or generalized seizures, wherein the seizure has not progressed to status epilepticus, wherein the treatment comprises oral administration of the medicament as an aerosol using an inhalation device which is breath-activated and delivers alprazolam while the patient takes a single inspiration through a mouthpiece without any other coordination needed, and wherein the device allows for self-administration.
2. The use according to claim 1, wherein the aerosol is to be delivered non-invasively to the deep lung, thereby producing reliable IV-like pharmacokinetics.
3. The use according to claim 1 or claim 2, wherein the treatment comprises stopping the seizure within two minutes of administration of the medicament.
4. The use according to any one of claims 1 to 3, wherein the device comprises a first element for heating the medicament to form a vapor, a second element allowing the vapor to cool, thereby forming a condensation aerosol, and a third element permitting inhalation of the aerosol.
5. The use according to any one of claims 1 to 4, wherein the subject is selected from patients with aura, focal seizures that secondarily generalize, or patients with juvenile myoclonic epilepsy whereby the seizure typically manifests over a period of minutes.
6. The use according to any one of claims 1 to 4, wherein the subject is a patient with cluster seizures, prolonged focal partial seizures, or juvenile myoclonic epilepsy.
7. The use according to any one of claims 1 to 6, wherein the medicament is to be administered when the subject experiences an aura.
8. The use according to any one of claims 1 to 7, wherein the subject is a patient with a focal seizure without impairment of consciousness/awareness. 26660232.1:DCC -
NZ795347A 2017-12-08 Method of treating epilepsy NZ795347B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62/432,353 2016-12-09
US62/485,281 2017-04-13

Publications (2)

Publication Number Publication Date
NZ795347A NZ795347A (en) 2025-01-31
NZ795347B2 true NZ795347B2 (en) 2025-05-01

Family

ID=

Similar Documents

Publication Publication Date Title
Zhu et al. Effects of long-duration wearing of N95 respirator and surgical facemask: a pilot study
FI3551189T3 (en) Alprazolam for use in treating epilepsy
Bakri et al. Comparison of dexmedetomidine and dexamethasone for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy
Owen et al. Effects of non-synchronised nasal intermittent positive pressure ventilation on spontaneous breathing in preterm infants
US10376657B2 (en) Medicinal vapor filtration system
GEP20227366B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
UA98136C2 (en) Use of aclidinium for the treatment of respiratory diseases
Gagnadoux et al. Validation of the System One RemStar Auto A-Flex for obstructive sleep apnea treatment and detection of residual apnea-hypopnea index: a European randomized trial
Zhao et al. Anesthesia for pediatric day-case dental surgery: a study comparing the classic laryngeal mask airway with nasal trachea intubation
Nascimento et al. Body position may influence oronasal CPAP effectiveness to treat OSA
NZ795347B2 (en) Method of treating epilepsy
Bae et al. The changes of cerebral hemodynamics during ketamine induced anesthesia in a rat model
Frossard et al. A40 A HARD DAY'S NIGHT: DRUG INDUCED LUNG DISEASE: Acute Uvulitis Secondary To Electronic Cigarette Use
Wu et al. Effect of oxygen-driven nebulization at different oxygen flows in acute exacerbation of chronic obstructive pulmonary disease patients
MX374032B (en) Endotracheal tube fastener for paediatric patients
Hayashida Neuroleptic malignant syndrome-induced disseminated intravascular coagulation: case report
Latimer Lung cancer: Smoking cessation
Pourdowlat et al. Is there a new indication and route of administration for an old drug in pulmonary hypertension (ph) secondary to COPD? A pilot study
Farid-Moayer et al. B67 DIAGNOSIS, TREATMENT, AND MANAGEMENT OF SLEEP DISORDERED BREATHING: Oral Pressure Therapy With A New Mouthpiece For Treatment Of Obstructive Sleep Apnea
Keidan et al. Electroencephalography for Children With Autistic Spectrum Disorder: A Sedation Protocol
Van Eyck et al. C70 SLEEP DISORDERED BREATHING IN PEDIATRIC AND ADULT MEDICAL DISORDERS: Sleep-Disordered Breathing And Thyroid Function In Obese Children And Adolescents
Baygin et al. Use of Midazolam Mixture as Premedication for Children Undergoing General Anesthesia for Dental Care
Lee et al. Awake during General Anesthesia with BispectralIndex Value of 35
Kiran et al. Upper airway obstruction in a patient following administration of fentanyl
Hussain et al. Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia